CN102065883A - 作为糖尿病患者血管重塑和心血管疾病治疗的治疗剂的未酰化生长素释放肽和类似物 - Google Patents

作为糖尿病患者血管重塑和心血管疾病治疗的治疗剂的未酰化生长素释放肽和类似物 Download PDF

Info

Publication number
CN102065883A
CN102065883A CN2009801222849A CN200980122284A CN102065883A CN 102065883 A CN102065883 A CN 102065883A CN 2009801222849 A CN2009801222849 A CN 2009801222849A CN 200980122284 A CN200980122284 A CN 200980122284A CN 102065883 A CN102065883 A CN 102065883A
Authority
CN
China
Prior art keywords
seq
cac
amino acid
polypeptide
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801222849A
Other languages
English (en)
Chinese (zh)
Inventor
玛丽亚·F·布里齐
贾姆皮罗·穆奇奥利
埃齐奥·吉戈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millendo Therapeutics SAS
Original Assignee
Alize Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alize Pharma SAS filed Critical Alize Pharma SAS
Publication of CN102065883A publication Critical patent/CN102065883A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2009801222849A 2008-06-13 2009-06-12 作为糖尿病患者血管重塑和心血管疾病治疗的治疗剂的未酰化生长素释放肽和类似物 Pending CN102065883A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6116308P 2008-06-13 2008-06-13
US61/061,163 2008-06-13
PCT/EP2009/057263 WO2009150214A2 (en) 2008-06-13 2009-06-12 Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease

Publications (1)

Publication Number Publication Date
CN102065883A true CN102065883A (zh) 2011-05-18

Family

ID=41078180

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801222849A Pending CN102065883A (zh) 2008-06-13 2009-06-12 作为糖尿病患者血管重塑和心血管疾病治疗的治疗剂的未酰化生长素释放肽和类似物

Country Status (8)

Country Link
US (2) US8476408B2 (https=)
EP (1) EP2310041B1 (https=)
JP (1) JP5481473B2 (https=)
CN (1) CN102065883A (https=)
AU (1) AU2009256558B2 (https=)
CA (1) CA2723270C (https=)
MX (1) MX2010013677A (https=)
WO (1) WO2009150214A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9651708B2 (en) * 2011-04-21 2017-05-16 Baker Hughes Incorporated Method of mapping reservoir fluid movement using gravity sensors
HRP20190062T1 (hr) * 2011-12-15 2019-03-08 Millendo Therapeutics Sas Fragmenti neaciliranog grelina za uporabu u liječenju prader-willi sindroma
US10016458B2 (en) 2012-04-16 2018-07-10 Baystate Health, Inc. p53 silenced endothelial progenitor cells for diabetes
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
EP3010529B1 (en) 2013-06-21 2020-05-06 Millendo Therapeutics SAS Use of unacylated ghrelin, fragments and analogs thereof as antioxidant
US10301609B2 (en) 2014-04-29 2019-05-28 Mayo Foundation For Medical Education And Research Butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin
WO2018053216A1 (en) 2016-09-15 2018-03-22 Mayo Foundation For Medical Education And Research Methods and materials for using butyrylcholinesterases to treat cancer
GB201918853D0 (en) * 2019-12-19 2020-02-05 Lund Lars H Methods of treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051389A2 (en) * 2001-12-18 2003-06-26 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
WO2005039624A1 (en) * 2003-10-24 2005-05-06 Theratechnologies Inc. Use of ghrelin and unacylated ghrelin compostions in insulin-related disease conditions
WO2008145749A1 (en) * 2007-05-31 2008-12-04 Alize Pharma Sas Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643872A (en) * 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5747296A (en) * 1992-05-11 1998-05-05 Corvas International, Inc. Method of detecting neutophil inhibitory factor mimics
EP0673384A4 (en) * 1992-12-10 1996-10-09 Univ Minnesota POLYPEPTIDES USEFUL IN TREATING INFLAMMABLE DISEASES.
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5695761A (en) * 1993-12-23 1997-12-09 Rutgers University Suppression of nitric oxide production by osteopontin
CA2184824A1 (en) * 1994-03-09 1995-09-14 Val S. Goodfellow Bradykinin antagonist peptides incorporating n-substituted glycines
US5958875A (en) * 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
US6627729B1 (en) 1997-03-24 2003-09-30 Zymogenetics, Inc. TML peptides
US5932548A (en) * 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
AU6515499A (en) * 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
AU2001228325A1 (en) 2000-02-01 2001-08-14 Novo-Nordisk A/S Use of compounds for the regulation of food intake
AU2001259056A1 (en) 2000-05-17 2001-11-26 Eli Lilly And Company Method for selectively inhibiting ghrelin action
CA2411667A1 (en) 2000-05-30 2001-12-06 Merck & Co. Inc. Ghrelin analogs
WO2002060477A1 (en) 2001-01-31 2002-08-08 Human Genome Sciences, Inc. Scaffolded fusion polypeptides, compositions for making the same and methods of using the same
WO2002060472A1 (fr) 2001-01-31 2002-08-08 Chugai Seiyaku Kabushiki Kaisha Remedes pour des etats d'hyponutrition
US7666833B2 (en) 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
CA2470235C (en) 2001-12-18 2012-02-07 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
EP2261250B1 (en) * 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
WO2003097083A1 (en) 2002-05-21 2003-11-27 Daiichi Suntory Pharma Co.,Ltd. Medicinal compositions containing ghrelin
JP2006527738A (ja) * 2003-06-18 2006-12-07 ディレボ・ビオテク・アーゲー 新規生物学的実体およびその薬学的または診断的使用
US7517269B2 (en) 2003-08-12 2009-04-14 Parvia Corp. Building element for constructing a modular substructure
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
KR20070034583A (ko) * 2004-07-14 2007-03-28 일라이 릴리 앤드 캄파니 항-그렐린 항체
EP1812044A2 (en) 2004-10-27 2007-08-01 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
CA2587627A1 (en) * 2004-11-15 2006-05-26 Eli Lilly And Company Desacyl ghrelin antibodies and therapeutic uses thereof
JP5147827B2 (ja) 2006-03-28 2013-02-20 リアット・ミンツ 高コレステロール血症および／または高コレステロールおよび／または高コレステロール関連疾患および／または脂血症および／または脂血症関連疾患および／または冠動脈疾患および／または体重管理および／または糖尿病および／または高血糖の治療のためのグレリンスプライス変種の使用
EP2067481A1 (en) 2007-12-03 2009-06-10 Charité-Universitätsmedizin Berlin Therapeutic use of desacyl ghrelin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051389A2 (en) * 2001-12-18 2003-06-26 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
WO2005039624A1 (en) * 2003-10-24 2005-05-06 Theratechnologies Inc. Use of ghrelin and unacylated ghrelin compostions in insulin-related disease conditions
WO2008145749A1 (en) * 2007-05-31 2008-12-04 Alize Pharma Sas Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GIANLUCA BALDANZI,ET AL.: ""Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT"", 《THE JOURNAL OF CELL BIOLOGY》 *
JOAO-BRUNO SOARES,ET AL.: ""Ghrelin, des-acyl ghrelin and obestatin: Three pieces of the same puzzle"", 《PEPTIDES》 *
LIAN LI. ET AL.: ""Cardioprotective effects of ghrelin and des-octanoyl ghrelin on myocarmyocardial"", 《ACTA PHARMACOLOGICA SINICA》 *
苗明三 等: "《常用医药研究动物模型》", 31 December 2007, 人民卫生出版社 *

Also Published As

Publication number Publication date
EP2310041A2 (en) 2011-04-20
US8476408B2 (en) 2013-07-02
CA2723270C (en) 2018-03-13
JP2011522864A (ja) 2011-08-04
WO2009150214A2 (en) 2009-12-17
EP2310041B1 (en) 2013-02-13
AU2009256558A1 (en) 2009-12-17
JP5481473B2 (ja) 2014-04-23
MX2010013677A (es) 2011-05-23
US20110160121A1 (en) 2011-06-30
US20100016226A1 (en) 2010-01-21
WO2009150214A3 (en) 2010-03-11
AU2009256558B2 (en) 2014-03-06
CA2723270A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
JP5481473B2 (ja) 糖尿病患者における血管リモデリングおよび心血管疾患治療のための治療薬としての非アシル化グレリンおよび類似体
Galsgaard et al. Disruption of glucagon receptor signaling causes hyperaminoacidemia exposing a possible liver-alpha-cell axis
Granata et al. Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic β-cells and human islets: involvement of 3′, 5′-cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl inositol 3-kinase/Akt signaling
US8455435B2 (en) Remedies for ischemia
Chen et al. Ghrelin induces cell migration through GHSR1a-mediated PI3K/Akt/eNOS/NO signaling pathway in endothelial progenitor cells
Gao et al. Sirtuin 3 governs autophagy‐dependent glycolysis during angiotensin II‐induced endothelial‐to‐mesenchymal transition
US8440617B2 (en) Hyperbaric treatment in wound healing
JP4177224B2 (ja) 胃切除術を受けた個体の低体重及び低体脂肪量を治療するためのグレリンの使用
US9550821B2 (en) Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin
JP5878922B2 (ja) 糖尿病血管合併症の治療
EP1900374B1 (en) Angiogenetic agent containing adrenomedulin as the active ingredient
KR102627084B1 (ko) 대사성 질환을 치료하기 위한 조성물 및 방법
US20160151458A1 (en) Use Of Unacylated Ghrelin, Fragments And Analogs Thereof As Antioxidant
JP5965397B2 (ja) 非アルコール性脂肪肝疾患の予防および治療のためのアデノウイルスａｄ３６ｅ４ｏｒｆ１タンパク質
JP2019512216A (ja) カルシウムチャネルのペプチド阻害剤
CA3201966A1 (en) Pre-treatment of msc with pparb/.delta. agonist for treatment of ischemia-reperfusion injury
WO2021021774A1 (en) Composition and method for promoting wound healing
US20020151500A1 (en) Method and compositions for treating hyperlipidemia and other conditions
EP1812045A2 (en) Uses of secretagogues for treatment of organ transplant patients
Lastra et al. Renin-angiotensin system proteases and the cardiometabolic syndrome: pathophysiological, clinical and therapeutic implications
Togliatto et al. unacylated ghrelin rescues endothelial progenitor cell function in TYPE 2 DIABETES INDIVIDUALS
Theurl et al. anuscript
Yang Peroxisome Proliferator-Activated Receptor γ Is Essential to Maintain Myocardial Redox Homeostasis: P33

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110518